The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Despite there being a valid 'cspec' property in the messages there's a discrepancy in message contents and CSPEC data: * Message Gene: MT-CO2 CSPEC Genes: [] * Message MONDOs: MONDO:0044970 CSPEC MONDO: []
  • No CSPEC computed assertion could be determined for this classification!


Variant: NC_012920.1(MT-CO2):m.8043_8044del

CA120606

9661 (ClinVar)

Gene: MT-CO2
Condition: mitochondrial disease
Inheritance Mode: Mitochondrial inheritance
UUID: 4e1b107b-fdb3-4c8d-95e7-fe5c1928b7a5
Approved on: 2024-01-22
Published on: 2025-06-12

HGVS expressions

NC_012920.1:m.8043_8044del
J01415.2:m.8043_8044del
ENST00000361739.1:c.458_459del

Uncertain Significance

Met criteria codes 2
PM2_Supporting PVS1_Strong
Not Met criteria codes 3
PP3 PS3 PS4

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Mitochondrial Disease Nuclear and Mitochondrial Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1_mtDNA

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Mitochondrial Diseases VCEP
The m.8043_8044del frameshift variant in MT-CO2 has been reported in one individual with primary mitochondrial disease to date, in an infant with severe lactic acidosis who died at 12 days old (PMID: 11471180). Complex IV deficiency was noted in skeletal and cardiac muscle. The variant was present at 20% heteroplasmy in skeletal muscle, 17% in cardiac muscle, 14% in lung tissue, 14% in liver, and 11.5% in skin. The variant was not assessed in proband’s blood and was undetectable in mother’s blood. Of note, nuclear genetic etiologies were not evaluated in this case. This variant causes a premature stop in the MT-CO2 gene resulting in truncation of 33% of the protein (PVS1_strong). This variant is absent in in the MITOMAP GenBank dataset, gnomAD v3.1.2, and the Helix dataset (PM2_supporting). There are no in silico predictors for this type of variant in mitochondrial DNA. There are no cybrids, single fiber studies, or other functional assays reported on this variant. This variant meets criteria to be classified as uncertain significance for primary mitochondrial disease. After extensive discussion, this Expert Panel agreed with this classification given low heteroplasmy levels in the only reported case with a severe phenotype, limited ability of technology used at the time to accurately report heteroplasmy, and because other genetic etiologies were not excluded in the only case reported. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on January 22, 2024. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PVS1_strong, PM2_supporting.
Met criteria codes
PM2_Supporting
This variant is absent in in the MITOMAP GenBank dataset, gnomAD v3.1.2, and the Helix dataset (PM2_supporting).
PVS1_Strong
This variant causes a premature stop in the MT-CO2 gene resulting in truncation of 33% of the protein (PVS1_strong).
Not Met criteria codes
PP3
There are no in silico predictors for this type of variant in mtDNA.
PS3
There are no cybrids, single fiber studies, or other functional assays reported on this variant.
PS4
The m.8043_8044del frameshift variant in MT-CO2 has been reported in one individual with primary mitochondrial disease to date, in an infant with severe lactic acidosis who died at 12 days old (PMID: 11471180). Complex IV deficiency was noted in skeletal and cardiac muscle. The variant was present at 20% heteroplasmy in skeletal muscle, 17% in cardiac muscle, 14% in lung tissue, 14% in liver, and 11.5% in skin.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.